[{"orgOrder":0,"company":"Virbac","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Milbemycin Oxime","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Virbac","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virbac \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Virbac \/ Merck"},{"orgOrder":0,"company":"Virbac","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Milbemycin Oxime","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Virbac","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virbac \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Virbac \/ Merck"}]

Find Clinical Drug Pipeline Developments & Deals by Virbac

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Merck Animal Health completion of its previously announced acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category from Virbac (NYSE Euronext:VIRP).

                          Brand Name : Sentinel

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 02, 2020

                          Lead Product(s) : Milbemycin Oxime,Lufenuron

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Merck Animal Health will acquire the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 13, 2020

                          Lead Product(s) : Milbemycin Oxime,Lufenuron

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank